BackChampions Oncology Overview

Champions Oncology Total Revenue

Latest total revenue for CSBR: $29M, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$13.84M

As of Apr 2026

Annual Revenue (TTM)

$28.87M
869.48% YoY

Trailing 12 months ending Apr 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Champions Oncology (CSBR) FAQ

The latest total revenue for CSBR is $29M as of April 2026. That compares with $3M in the prior-year period — up 869.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Champions Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, CSBR's total revenue moved from $3M to $29M — a 869.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Champions Oncology's operating scale or balance-sheet position.

Against Healthcare companies, CSBR currently prints $29M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Champions Oncology's growth, margins, and balance sheet.

A total revenue figure of $29M for CSBR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting CSBR's total revenue ($29M), review year-over-year change from $3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.